|
US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
AU612370B2
(en)
|
1987-05-21 |
1991-07-11 |
Micromet Ag |
Targeted multifunctional proteins
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
ES2284161T3
(es)
|
1990-01-12 |
2007-11-01 |
Amgen Fremont Inc. |
Generacion de anticuerpos xenogenicos.
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
AU8507191A
(en)
|
1990-08-29 |
1992-03-30 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6770274B1
(en)
|
1990-09-14 |
2004-08-03 |
The General Hospital Corporation |
Viral mutant HSV mediated destruction of neoplastic cells
|
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
|
JP3266311B2
(ja)
|
1991-05-02 |
2002-03-18 |
生化学工業株式会社 |
新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
|
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
|
US5871907A
(en)
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
US5858657A
(en)
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
|
US5855885A
(en)
|
1993-01-22 |
1999-01-05 |
Smith; Rodger |
Isolation and production of catalytic antibodies using phage technology
|
|
US5728379A
(en)
|
1994-06-23 |
1998-03-17 |
Georgetown University |
Tumor- or cell-specific herpes simplex virus replication
|
|
US5585096A
(en)
|
1994-06-23 |
1996-12-17 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
|
US6699468B1
(en)
|
1994-06-23 |
2004-03-02 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
|
US5702892A
(en)
|
1995-05-09 |
1997-12-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Phage-display of immunoglobulin heavy chain libraries
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
|
US5824318A
(en)
|
1996-07-24 |
1998-10-20 |
American Cyanamid Company |
Avirulent herpetic viruses useful as tumoricidal agents and vaccines
|
|
ATE549918T1
(de)
|
1996-12-03 |
2012-04-15 |
Amgen Fremont Inc |
Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
|
|
US6057098A
(en)
|
1997-04-04 |
2000-05-02 |
Biosite Diagnostics, Inc. |
Polyvalent display libraries
|
|
US6379674B1
(en)
|
1997-08-12 |
2002-04-30 |
Georgetown University |
Use of herpes vectors for tumor therapy
|
|
AU2546399A
(en)
|
1998-02-10 |
1999-08-30 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Preparations with controlled release
|
|
KR100508289B1
(ko)
|
1998-04-21 |
2005-08-17 |
마이크로메트 에이지 |
Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
|
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
|
EP1141338A4
(en)
|
1998-12-31 |
2002-09-25 |
Arch Dev Corp |
RECOMBINANT HERPES SIMPLEX VIRUS FOR TREATING NEOPLASTIC DISEASES
|
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
|
AU2905199A
(en)
|
1999-03-15 |
2000-10-04 |
Trustees Of The University Of Pennsylvania, The |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
US6764675B1
(en)
|
1999-06-08 |
2004-07-20 |
The Uab Research Foundation |
Herpes simplex virus expressing foreign genes and method for treating cancers therewith
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
ATE312189T1
(de)
|
2000-01-21 |
2005-12-15 |
Biovex Ltd |
Virusstämme für die onkolytische behandlung von krebs
|
|
EP1257289A1
(en)
|
2000-02-08 |
2002-11-20 |
The Penn State Research Foundation |
Immunotherapy using interleukin 13 receptor subunit alpha 2
|
|
ES2366608T3
(es)
|
2001-03-27 |
2011-10-21 |
The General Hospital Corporation |
Vectores víricos y su uso en métodos terapéuticos.
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
MXPA04004167A
(es)
|
2001-11-05 |
2004-07-08 |
Zymogenetics Inc |
Antagonistas de interleucina-21.
|
|
DE60226641D1
(de)
|
2001-12-03 |
2008-06-26 |
Amgen Fremont Inc |
Antikörperkategorisierung auf der grundlage von bindungseigenschaften
|
|
ES2382800T3
(es)
|
2002-01-18 |
2012-06-13 |
Zymogenetics, Inc. |
Multímeros Zcytor17 receptores de citocinas
|
|
US7736652B2
(en)
|
2002-03-21 |
2010-06-15 |
The Regents Of The University Of California |
Antibody fusion proteins: effective adjuvants of protein vaccination
|
|
DK1531850T3
(da)
|
2002-06-07 |
2012-06-04 |
Zymogenetics Inc |
Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
|
|
EP1551505B1
(en)
|
2002-10-04 |
2010-02-24 |
Microchips, Inc. |
Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
|
|
CN1513993A
(zh)
*
|
2002-12-31 |
2004-07-21 |
北京博泰迪生物工程科技开发有限公司 |
中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
|
|
AU2004242846A1
(en)
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
|
|
JP2007506789A
(ja)
|
2003-09-25 |
2007-03-22 |
ザイモジェネティクス， インコーポレイテッド |
Ｉｌ−２１を用いた自己免疫疾患の治療方法
|
|
ZA200601699B
(en)
|
2003-10-16 |
2007-05-30 |
Micromet Ag |
Multispecific deimmunized CD3-binders
|
|
MXPA06014075A
(es)
|
2004-06-03 |
2007-03-15 |
Novimmune Sa |
Anticuerpos anti-cd3 y metodos de uso de los mismos.
|
|
US7731952B2
(en)
|
2004-06-24 |
2010-06-08 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
CA2599925A1
(en)
|
2005-03-14 |
2006-09-21 |
Merck & Co., Inc. |
Cgrp receptor antagonists
|
|
MX2007012887A
(es)
|
2005-04-18 |
2007-12-10 |
Novo Nordisk As |
Variantes il-21.
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
JP2009517406A
(ja)
|
2005-11-28 |
2009-04-30 |
ザイモジェネティクス， インコーポレイテッド |
Ｉｌ−２１受容体アンタゴニスト
|
|
EP2805971A1
(en)
|
2005-11-28 |
2014-11-26 |
ZymoGenetics, Inc. |
IL-21 antagonists
|
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
|
KR20090008467A
(ko)
|
2006-05-08 |
2009-01-21 |
필로겐 에스.피.에이. |
치료용의 항체표적 사이토카인
|
|
WO2008049920A2
(en)
|
2006-10-26 |
2008-05-02 |
Novo Nordisk A/S |
Il-21 variants
|
|
WO2008074863A1
(en)
|
2006-12-21 |
2008-06-26 |
Novo Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
|
CN101230334B
(zh)
|
2007-01-22 |
2011-06-01 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
|
CN101230335B
(zh)
|
2007-01-22 |
2010-08-11 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
|
SG10201808730VA
(en)
|
2007-04-03 |
2018-11-29 |
Amgen Res Munich Gmbh |
Cross-species-specific binding domain
|
|
CN109456410B
(zh)
|
2007-04-03 |
2022-01-28 |
安进研发（慕尼黑）股份有限公司 |
跨物种特异性CD3-ε结合结构域
|
|
EP2139458A4
(en)
|
2007-04-19 |
2013-01-23 |
Dong A Pharm Co Ltd |
BIODEGRADABLE MICRO BEADS COMPOSITION FOR CONTROLLED RELEASE OF GLUCOSE-CONTROLLED PEPTIDE AND FORMULATION THEREOF
|
|
EP3103813A1
(en)
|
2007-12-07 |
2016-12-14 |
ZymoGenetics, Inc. |
Anti-human il-21 monoclonal antibodies
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
CN102089325A
(zh)
|
2008-04-17 |
2011-06-08 |
埃博灵克斯股份有限公司 |
能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
|
|
EP4180458A1
(en)
|
2008-10-01 |
2023-05-17 |
Amgen Research (Munich) GmbH |
Cross-species-specific psma x cd3 bispecific single chain antibody
|
|
WO2010103038A1
(en)
*
|
2009-03-11 |
2010-09-16 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
|
LT2975051T
(lt)
|
2009-06-26 |
2021-07-12 |
Regeneron Pharmaceuticals, Inc. |
Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
|
|
PE20120630A1
(es)
|
2009-08-17 |
2012-05-26 |
Roche Glycart Ag |
Inmunoconjugados dirigidos
|
|
CN102741280B
(zh)
|
2009-10-30 |
2015-12-02 |
诺维信生物制药丹麦公司 |
白蛋白变体
|
|
PT2542590T
(pt)
|
2010-03-05 |
2017-08-31 |
Univ Johns Hopkins |
Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
|
|
US20130225496A1
(en)
|
2010-11-01 |
2013-08-29 |
Novozymes Biopharma Dk A/S |
Albumin Variants
|
|
RU2013139267A
(ru)
|
2011-02-10 |
2015-03-20 |
Рош Гликарт Аг |
Улучшенная иммунотерапия
|
|
CA2829628A1
(en)
|
2011-03-11 |
2012-09-20 |
Amgen Inc. |
Method of correlated mutational analysis to improve therapeutic antibodies
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
MX353816B
(es)
|
2011-05-05 |
2018-01-30 |
Albumedix As |
Variantes de albumina.
|
|
EP3626739A1
(en)
|
2011-06-24 |
2020-03-25 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
WO2013006795A2
(en)
|
2011-07-07 |
2013-01-10 |
Humanitas International Foundation |
Antiviral compositions and methods of their use
|
|
HRP20182194T1
(hr)
|
2011-09-08 |
2019-02-22 |
New York University |
Onkolitički herpes simpleks virus i njegova terapeutska uporaba
|
|
WO2013059885A2
(en)
*
|
2011-10-28 |
2013-05-02 |
Cephalon Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
HK1200842A1
(en)
|
2011-11-18 |
2015-08-14 |
Albumedix Ltd |
Proteins with improved half-life and other properties
|
|
WO2013096732A2
(en)
|
2011-12-23 |
2013-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of treating or preventing viral diseases by blocking interleukin-21
|
|
WO2013109904A1
(en)
|
2012-01-19 |
2013-07-25 |
University Of Miami |
Compositions, methods and kits for treatment of cancer and autoimmune diseases
|
|
MX2014010278A
(es)
|
2012-03-16 |
2015-03-05 |
Novozymes Biopharma Dk As |
Variantes de albumina.
|
|
WO2013164694A1
(en)
|
2012-04-30 |
2013-11-07 |
Biocon Limited |
Targeted/immunomodulatory fusion proteins and methods for making same
|
|
EP2847219A1
(en)
|
2012-05-07 |
2015-03-18 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
|
WO2013169693A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
AR092044A1
(es)
|
2012-08-07 |
2015-03-18 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
WO2014072481A1
(en)
|
2012-11-08 |
2014-05-15 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
|
WO2014139468A1
(en)
|
2013-03-15 |
2014-09-18 |
Admark Healthcare, Llc |
Fusion protein molecules and method of use
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
WO2015000585A1
(en)
*
|
2013-07-02 |
2015-01-08 |
Walter Sebald |
Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
|
|
EP3019533B1
(en)
|
2013-07-11 |
2020-01-08 |
The Scripps Research Institute |
Coiled coil immunoglobulin fusion proteins and compositions thereof
|
|
HUE046249T2
(hu)
|
2013-12-12 |
2020-02-28 |
Shanghai hengrui pharmaceutical co ltd |
PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
EP3102594A1
(en)
|
2014-02-06 |
2016-12-14 |
F. Hoffmann-La Roche AG |
Interleukine 10 immunoconjugates
|
|
RU2689160C2
(ru)
|
2014-02-19 |
2019-05-24 |
Мерк Патент Гмбх |
Противораковая таргетная иммунотерапия с применением il-12
|
|
SI3128997T1
(sl)
|
2014-04-08 |
2020-11-30 |
Boston Pharmaceuticals Inc. |
Vezavne molekule specifične za IL-21 in njihove uporabe
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
WO2016100375A2
(en)
|
2014-12-15 |
2016-06-23 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
EP3233120A4
(en)
|
2014-12-19 |
2018-05-30 |
Monash University |
Il-21 antibodies
|
|
EP3233914A1
(en)
|
2014-12-19 |
2017-10-25 |
Mabtech Ab |
Composition, kit and method for inhibition of il-21 mediated activation of human cells
|
|
KR20160113452A
(ko)
|
2015-03-20 |
2016-09-29 |
(주)엘지하우시스 |
진공 단열재용 심재 및 진공단열재
|
|
AU2016298227B9
(en)
|
2015-07-30 |
2019-10-31 |
Macrogenics, Inc. |
PD-1-binding molecules and methods of use thereof
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
WO2017023779A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
MX392711B
(es)
|
2015-08-11 |
2025-03-24 |
Wuxi Biologics Ireland Ltd |
Anticuerpos anti-pd-1 novedosos.
|
|
EP3344656A1
(en)
|
2015-09-01 |
2018-07-11 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
|
AU2016329251B2
(en)
|
2015-10-02 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Anti-PD1 antibodies and methods of use
|
|
KR20250099459A
(ko)
|
2015-11-03 |
2025-07-01 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 그의 용도
|
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
|
HUE063377T2
(hu)
|
2015-12-22 |
2024-01-28 |
Regeneron Pharma |
Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
|
|
WO2017118866A1
(en)
|
2016-01-08 |
2017-07-13 |
Replimune Limited |
Engineered virus
|
|
US20210000921A1
(en)
|
2016-01-11 |
2021-01-07 |
Flagship Pioneering Innovations V. Inc. |
Methods and compositions for modulating thymic function
|
|
SG11201805770UA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
CA3011942A1
(en)
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
WO2017136818A2
(en)
|
2016-02-05 |
2017-08-10 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
CN116769054A
(zh)
|
2016-02-05 |
2023-09-19 |
奥里尼斯生物科学私人有限公司 |
双特异性信号传导剂及其用途
|
|
US11186641B2
(en)
|
2016-03-17 |
2021-11-30 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
JP7082604B2
(ja)
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
|
KR102694879B1
(ko)
|
2016-04-01 |
2024-08-16 |
암젠 인크 |
Flt3에 대한 키메라 수용체 및 이의 사용 방법
|
|
RU2751236C2
(ru)
|
2016-04-22 |
2021-07-12 |
Иммвира Ко., Лимитед |
КОНСТРУИРОВАНИЕ ОБЛИГАТНОГО ВЕКТОРА НА ОСНОВЕ ОНКОЛИТИЧЕСКИХ ВИРУСОВ ПРОСТОГО ГЕРПЕСА (oHSV) И КОНСТРУКЦИИ ДЛЯ ТЕРАПИИ РАКА
|
|
CN109983121A
(zh)
|
2016-06-30 |
2019-07-05 |
昂克诺斯公司 |
治疗性多肽的假型化溶瘤病毒递送
|
|
RU2656181C1
(ru)
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
|
WO2018026872A1
(en)
|
2016-08-01 |
2018-02-08 |
Virogin Biotech Canada Ltd |
Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
|
|
KR101928981B1
(ko)
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
|
|
CA3036912C
(en)
|
2016-09-14 |
2022-06-07 |
Beijing Hanmi Pharm. Co., Ltd. |
Antibody specifically binding to pd-1 and functional fragment thereof
|
|
JP7101169B2
(ja)
|
2016-09-21 |
2022-07-14 |
シーストーン ファーマシューティカルズ |
プログラム死１（ｐｄ－１）に対する新規モノクローナル抗体
|
|
US20190209652A1
(en)
|
2016-09-23 |
2019-07-11 |
Oncosec Medical Incorporated |
Modulating responses to checkpoint inhibitor therapy
|
|
RS62589B1
(sr)
|
2016-11-02 |
2021-12-31 |
Jounce Therapeutics Inc |
Antitela na pd-1 i njihova upotreba
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
EP4201953A1
(en)
|
2017-04-03 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
CN111094330A
(zh)
|
2017-07-03 |
2020-05-01 |
转矩医疗股份有限公司 |
编码免疫刺激融合分子的多核苷酸及其用途
|
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
US20210024631A1
(en)
|
2018-03-28 |
2021-01-28 |
Orionis Biosciences, Inc. |
Bi-functional proteins and construction thereof
|
|
UY38182A
(es)
|
2018-04-10 |
2019-10-31 |
Amgen Inc |
Receptores quiméricos de dll3 y métodos para su uso
|
|
EP3807321A4
(en)
|
2018-06-18 |
2022-03-02 |
Anwita Biosciences, Inc. |
ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF
|
|
EP3856229A1
(en)
|
2018-09-28 |
2021-08-04 |
Pierre Fabre Medicament |
New immunocytokines for the treatment of cancer
|
|
JP7797198B2
(ja)
|
2018-12-21 |
2026-01-13 |
オーエスイー・イミュノセラピューティクス |
ヒトｐｄ－１に対する二機能性分子
|